tbuckley/cabot-search huggingface dataset:
Performance of Four Frailty Classifications in Older Patients With Cancer: Prospective Elderly Cancer Patients Cohort Study
Authors: Emilie Ferrat, Elena Paillaud, Philippe Caillet, Marie Laurent, Christophe Tournigand, Jean-Léon Lagrange, Jean-Pierre Droz, Lodovico Balducci, Etienne Audureau, Florence Canouï-Poitrine, Sylvie Bastuji-Garin
Journal: Journal of Clinical Oncology (2017)

Purpose Frailty classifications of older patients with cancer have been developed to assist physicians in selecting cancer treatments and geriatric interventions. They have not been compared, and their performance in predicting outcomes has not been assessed. Our objectives were to assess agreement among four classifications and to compare their predictive performance in a large cohort of in- and outpatients with various cancers. Patients and Methods We prospectively included 1,021 patients age 70 years or older who had solid or hematologic malignancies and underwent a geriatric assessment in one of two French teaching hospitals between 2007 and 2012. Among them, 763 were assessed using four classifications: Balducci, International Society of Geriatric Oncology (SIOG) 1, SIOG2, and a latent class typology. Agreement was assessed using the κ statistic. Outcomes were 1-year mortality and 6-month unscheduled admissions. Results All four classifications had good discrimination for 1-year mortality (C-index ≥ 0.70); discrimination was best with SIOG1. For 6-month unscheduled admissions, discrimination was good with all four classifications (C-index ≥ 0.70). For classification into three (fit, vulnerable, or frail) or two categories (fit v vulnerable or frail and fit or vulnerable v frail), agreement among the four classifications ranged from very poor (κ ≤ 0.20) to good (0.60 < κ ≤ 0.80). Agreement was best between SIOG1 and the latent class typology and between SIOG1 and Balducci. Conclusion These four frailty classifications have good prognostic performance among older in- and outpatients with various cancers. They may prove useful in decision making about cancer treatments and geriatric interventions and/or in stratifying older patients with cancer in clinical trials.
Lack of healthcare funding in Greece is putting patients’ lives at risk
Authors: Julianna Photopoulos
Journal: BMJ (2017)

Greece’s public health sector is facing major shortages of staff, medical supplies, and equipment after seven years of austerity measures, and latest figures show an increase in numbers of life threatening infections and deaths.

“Our public health system is in meltdown owing to continual cutbacks in healthcare,” said Michalis Giannakos, head of the Panhellenic Federation of Public Hospital Employees. “Hospitals are underfunded and understaffed, putting patients’ lives at risk. People who might otherwise survive are dying.”

Latest available figures from the European Centre for Disease Prevention and Control for 2011-12 showed that about 9% of patients admitted to hospitals in Greece developed hospital acquired infections, accounting for an estimated 3000 deaths a year.1 …
Evidence for CD19+ (B) CD8+ (T)-Cell Interactions in Blood and Tissues from Patients with Graft-Versus-Host Disease
Authors: Sara Deola, Chiara Cugno, Patrizia Comoli, Ilaria Guido, Laura Rubert, Marco Zecca, Diego Zanolini, Antonia Follenzi, Martin Langes, Giovanni Negri, Martina Tauber, Irene Pusceddu, Irene Cavattoni, Mirija Svaldi, Ena Wang, Sergio Rutella, Francesco M Marincola
Journal: Blood (2015)
High prevalence of mutantKRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients
Authors: K. Allenson, J. Castillo, F.A. San Lucas, G. Scelo, D.U. Kim, V. Bernard, G. Davis, T. Kumar, M. Katz, M.J. Overman, L. Foretova, E. Fabianova, I. Holcatova, V. Janout, F. Meric-Bernstam, P. Gascoyne, I. Wistuba, G. Varadhachary, P. Brennan, S. Hanash, D. Li, A. Maitra, H. Alvarez
Journal: Annals of Oncology (2017)
New Derivatives of L-Idonojirimycin Working As Pharmacological Chaperones for the Treatment of Gaucher Disease
Authors: Pilar Alfonso, Javier Gervas, Vanesa Andreu, Joaquin Navascues, Francisca Sanchez-Jimenez, Miguel Pocovi, Carmen Ortiz-Mellet, Jose M Garcia-Fernandez, Pilar Giraldo
Journal: Blood (2012)
RIPK1 protects hepatocytes from Kupffer cells-mediated TNF-induced apoptosis in mouse models of PAMP-induced hepatitis
Authors: Aveline Filliol, Claire Piquet-Pellorce, Céline Raguénès-Nicol, Sarah Dion, Muhammad Farooq, Catherine Lucas-Clerc, Peter Vandenabeele, Mathieu J.M. Bertrand, Jacques Le Seyec, Michel Samson
Journal: Journal of Hepatology (2017)
High-Grade Primary Gastric Lymphoma: A Retrospective Review of Clinicopathologic Features and Prognostic Factor Analysis in 214 Patients with High-Grade Gastric Lymphoma.
Authors: Yeon Hee Park, Won Seog Kim, Soo-Mee Bang, Soon Lee, Ji Eun Uhm, Hye Jin Kang, ImII, Baek-Yeol Ryoo, Sung Hyun Yang, Kihyun Kim, Seung Sook Lee, Young H. Ko, Keunchil Park
Journal: Blood (2005)
Inhibiting Insulin-Mediated β <sub>2</sub> -Adrenergic Receptor Activation Prevents Diabetes-Associated Cardiac Dysfunction
Authors: Qingtong Wang, Yongming Liu, Qin Fu, Bing Xu, Yuan Zhang, Sungjin Kim, Ruensern Tan, Federica Barbagallo, Toni West, Ethan Anderson, Wei Wei, E. Dale Abel, Yang K. Xiang
Journal: Circulation (2016)

Type 2 diabetes mellitus (DM) and obesity independently increase the risk of heart failure by incompletely understood mechanisms. We propose that hyperinsulinemia might promote adverse consequences in the hearts of subjects with type-2 DM and obesity.High-fat diet feeding was used to induce obesity and DM in wild-type mice or mice lacking β2-adrenergic receptor (β2AR) or β-arrestin2. Wild-type mice fed with high-fat diet were treated with a β-blocker carvedilol or a GRK2 (G-protein-coupled receptor kinase 2) inhibitor. We examined signaling and cardiac contractile function.High-fat diet feeding selectively increases the expression of phosphodiesterase 4D (PDE4D) in mouse hearts, in concert with reduced protein kinase A phosphorylation of phospholamban, which contributes to systolic and diastolic dysfunction. The expression of PDE4D is also elevated in human hearts with DM. The induction of PDE4D expression is mediated by an insulin receptor, insulin receptor substrate, and GRK2 and β-arrestin2-dependent transactivation of a β2AR-extracellular regulated protein kinase signaling cascade. Thus, pharmacological inhibition of β2AR or GRK2, or genetic deletion of β2AR or β-arrestin2, all significantly attenuate insulin-induced phosphorylation of extracellular regulated protein kinase and PDE4D induction to prevent DM-related contractile dysfunction.These studies elucidate a novel mechanism by which hyperinsulinemia contributes to heart failure by increasing PDE4D expression and identify β2AR or GRK2 as plausible therapeutic targets for preventing or treating heart failure in subjects with type 2 DM.
Rituximab, Lenalidomide, and Bortezomib in the First-Line or Second-Line Treatment of Patients with Mantle Cell Lymphoma a Phase I/II Trial.
Authors: Ian W. Flinn, Mark Mainwaring, Nancy Peacock, Dianna Shipley, Edward Arrowsmith, Michael R. Savona, John D. Hainsworth, Jesus G. Berdeja
Journal: Blood (2012)
Clinical and Prognostic Relevance of Magnetic Resonance Imaging of the Spine in Newly Diagnosed Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation.
Authors: Patrizia Tosi, Alessandro Petrucci, Lucia Pantani, Elena Zamagni, Paola Tacchetti, Giulia Perrone, Annamaria Brioli, Michela Ceccolini, Michele Baccarani, Michele Cavo
Journal: Blood (2009)
Anti-Myeloma Activity of the Maytansinoid Immunoconjugate of Internalizing Human Monoclonal Antibody Specific for HM1.24/BST2 (CD317).
Authors: Shuji Ozaki, Takafumi Tomura, Etsuko Sekimoto, Yoichi Tanaka, Kenichi Kitazoe, Jin Asano, Toshihiro Hashimoto, Masahiro Abe, Takayuki Furuta, Tomoyuki Tahara, Isao Ishida, Shiro Kataoka, Toshio Matsumoto
Journal: Blood (2005)
Cytogenetic Risk Remains a Major Predictor of Outcome in Pediatric AML and ALL Treated with Allogeneic Stem Cell Transplantation,
Authors: Claudia Ulrike Walter, Mouhab Ayas, Amal Alseraihy, Hassan El-Solh, Abdullah Al-Jefri, Ali Al-Ahmari, Asim F Belgaumi, Maher Albitar
Journal: Blood (2011)
5’UTR point substitutions and N-terminal truncating mutations of ANKRD26 in acute myeloid leukemia
Authors: Caterina Marconi, Ilaria Canobbio, Valeria Bozzi, Tommaso Pippucci, Giorgia Simonetti, Federica Melazzini, Silvia Angori, Giovanni Martinelli, Giuseppe Saglio, Mauro Torti, Ira Pastan, Marco Seri, Alessandro Pecci
Journal: Journal of Hematology & Oncology (2017)

Thrombocytopenia 2 (THC2) is an inherited disorder caused by monoallelic single nucleotide substitutions in the 5'UTR of the ANKRD26 gene. Patients have thrombocytopenia and increased risk of myeloid malignancies, in particular, acute myeloid leukemia (AML). Given the association of variants in the ANKRD26 5'UTR with myeloid neoplasms, we investigated whether, and to what extent, mutations in this region contribute to apparently sporadic AML. To this end, we studied 250 consecutive, non-familial, adult AML patients and screened the first exon of ANKRD26 including the 5'UTR. We found variants in four patients. One patient had the c.-125T>G substitution in the 5'UTR, while three patients carried two different variants in the 5' end of the ANKRD26 coding region (c.3G>A or c.105C>G). Review of medical history showed that the patient carrying the c.-125T>G was actually affected by typical but unrecognized THC2, highlighting that some apparently sporadic AML cases represent the evolution of a well-characterized familial predisposition disorder. As regards the c.3G>A and the c.105C>G, we found that both variants result in the synthesis of N-terminal truncated ANKRD26 isoforms, which are stable and functional in cells, in particular, have a strong ability to activate the MAPK/ERK signaling pathway. Moreover, investigation of one patient with the c.3G>A showed that mutation was associated with strong ANKRD26 overexpression in vivo, which is the proposed mechanism for predisposition to AML in THC2 patients. These data provide evidence that N-terminal ANKRD26 truncating mutations play a potential pathogenetic role in AML. Recognition of AML patients with germline ANKRD26 pathogenetic variants is mandatory for selection of donors for bone marrow transplantation.
B and T-Cell Lymphoma Patient-Derived Xenografts Recapitulate Aspects of Disease Biology and Progression and Represent Novel Tools for Preclinical Drug Development
Authors: Amanda L Christie, Alexandra N. Christodoulou, Tiffany DeSouza, Mark A. Murakami, Loretta S. Li, Nadja Kopp, Raphael Koch, Abner Louissaint, Samuel Y. Ng, Caron A. Jacobson, Brent Shoji, Matthew S. Davids, Oreofe O. Odejide, Ann S. LaCasce, David C. Fisher, Arnold S. Freedman, Eric D. Jacobsen, Monica Bertagnolli, Geraldine S Pinkus, David M. Dorfman, Elizabeth A. Morgan, Jon C Aster, Margaret A. Shipp, David M. Weinstock
Journal: Blood (2015)
Hematopoietic Stem Cell Transplant (HSCT) as Primary Treatment for T-Cell Lymphobastic Lymphoma (T-LBL) : An Intention to Treat Analysis.
Authors: Kevin W. Song, Thomas J. Nevill, Randy D. Gascoyne, Cynthia L. Toze, Michael B. Barnett, Donna L. Forrest, Donna E. Hogge, Julye C. Lavoie, Stephen H. Nantel, John D. Shepherd, Clayton A. Smith, Heather J. Sutherland, Nicholas J. Voss, Joseph M. Connors
Journal: Blood (2004)
University fresher campaign doubles meningitis vaccination rate, UK study finds
Authors: Susan Mayor
Journal: BMJ (2017)

A campaign asking freshers arriving at university whether they had been vaccinated against meningitis and offering free vaccination to unvaccinated students more than doubled meningococcal ACWY (MenACWY) vaccine coverage, a UK study has found.1

Cases of group W invasive meningococcal disease have increased steadily in England since 2009 owing to the rapid expansion of a hypervirulent strain (Men W ST-11 cc) that is associated with more severe meningitis than group B disease.

In response, Public Health England introduced a vaccination campaign in 2015 …
The Impact of Geographic Proximity to Transplant Center on Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Karim E. Abou-Nassar, Haesook T. Kim, Joseph H. Antin, Vincent T. Ho, Robert J. Soiffer, Corey Cutler, Edwin P Alyea, John Koreth, Philippe Armand
Journal: Blood (2010)
Erythropoiesis in Polycythemia Vera Is Hyper-Proliferative and Has Accelerated Differentiation during In Vitro Erythroid Expansion and Is Associated with Higher Expressions of cMYB and EPOR at Early Erythroid Progenitors
Authors: Hana Bruchova, Donghoon Yoon, Archana Agarwal, Eva Otahalova, Hyojin Kim, Josef T. Prchal
Journal: Blood (2007)
Sustained Hemostatic Platelet Counts in Adults with Immune Thrombocytopenia (ITP) Following Cessation of Treatment with the TPO Receptor Agonist Romiplostim: Report of 9 Cases,
Authors: James B Bussel, Francesco Rodeghiero, Roger M. Lyons, Barry Firstenberg, Joanne Joseph, Craig M. Kessler, Louis Terriou, Roberto Stasi, Paul Chang, Susie Jun
Journal: Blood (2011)
The Prevalent, Features and Prognostic Impact of Deletion p16 in Patients with Adult Acute Lymphoblastic Leukemia
Authors: Na Xu, Yulin Li, Xuan Zhou, Liu Xiaoli, Hongsheng Zhou, Fen Huang, Bing Xu, Qifa Liu, Jing Sun, Ru Feng, Fanyi Meng
Journal: Blood (2014)
Rapamycin, Inhibitor of Mtor Kinase, Sensitizes Leukemia Cells to Fludarabine-Induced Apoptosis, but Protects Survival of Normal Lymphocytes.
Authors: Piotr Smolewski, Barbara Cebula, Dorota Wierzbicka, Anna Linke, Krzysztof Jamroziak, Mikhail V. Blagosklonny, Zbigniew Darzynkiewicz, Tadeusz Robak
Journal: Blood (2004)
Transfusion Practices in Myelodysplastic Syndromes: Preliminary Results of An Epidemiologic and Economical Study
Authors: Matthieu Filloux, Adrien Chauchet, Yvan Beaussant, Chrystelle Vidal, Franck Leroux, Delphine Binda, Marie-Christine Woronoff-Lemsi, Remy Contreras, Françoise Schillinger, Etienne Daguindau, Laurent Bardiaux, Eric Deconinck
Journal: Blood (2011)
Multi-Center Analysis of the Effect of Disease Subtype and Minimal Residual Disease on Allogeneic Stem Cell Transplantation Outcomes in T-Cell Acute Lymphoblastic Leukemia (T-ALL)
Authors: Jonathan E. Brammer, Rima M Saliba, Jeffrey L. Jorgensen, Celina Ledesma, Gabriela Rondon, Michelle Poon, Liang Piu Koh, William Dibb, Guang Fan, Cynthia K Saliba, Sa Wang, Uday R. Popat, Elizabeth J. Shpall, Farhad Ravandi, Hagop Kantarjian, Richard Thomas Maziarz, Richard E. Champlin, Chitra M. Hosing, Partow Kebriaei
Journal: Blood (2015)
Hypoxia-Adapted CML Cells Are More Primitive Population and Are Eradicated by Glyoxalase-1 Inhibitors.
Authors: Miki Takeuchi, Shinya Kimura, Junya Kuroda, Eishi Ashihara, Makoto Kawatani, Hiroyuki Osada, Kazuo Umezawa, Eiko Yasui, Masaya Imoto, Takashi Tsuruo, Asumi Yokota, Ruriko Tanaka, Rina Nagao, Tatsutoshi Nakahata, Yoshihide Fujiyama, Taira Maekawa
Journal: Blood (2009)
A Transgenic Mouse Model of Aggressive B-Cell Malignancy for Evaluating Anti-Human CD37 Therapeutics
Authors: Kyle A Beckwith, Frank W Frissora, Matthew R Stefanovski, Jutta Deckert, Carlo M Croce, Xiaokui Mo, David Jarjoura, John C. Byrd, Natarajan Muthusamy
Journal: Blood (2012)
Unrelated Transplants for Poor Prognosis Adult Acute Lymphoblastic Leukemia: Long-Term Comparative Analysis Based on the Hematopoietic Progenitor Source.
Authors: Christelle Ferra, Jaime Sanz, Rafael Camara, Guillermo Sanz, Arancha Bermudez, David Valcarcel, Montserrat Rovira, David Serrano, Dolores Caballero, Ildefonso Espigado, Mireia Morgades, Inmaculada Heras, Carlos Solano, Cristina Barrenetxea, Rafael Duarte, Ana Garcia-Noblejas, José Luis Diez, Arturo Iriondo, Enric Carreras, Jordi Sierra, Miguel A. Sanz, Josep M. Ribera
Journal: Blood (2008)
Successful PBSC Mobilization, Collection, Transplantation and Engraftment after Radioimmunotherapy with Yttrium-90 Ibritumomab Tiuxetan for Non-Hodgkin’s Lymphoma (NHL).
Authors: Pamela Ely, Diane M. Stearns, Bassem I. Zaki, Thomas F. Fitzmaurice, Marc Gautier, Christopher H. Lowrey, Elizabeth M. Bengtson, John M. Hill, Anna D. Schaal, Elizabeth A. Kimtis, Lynn Root, Susan Webber, Zbigniew M. Szczepiorkowski, Kenneth R. Meehan
Journal: Blood (2005)
Efficacy and Safety Results of Prolong-9FP Clinical Program of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Hemophilia B
Authors: Elena Santagostino, Christine Voigt, Denise Wolko, Grace Cole, Yanyan Li, Iris C. Jacobs
Journal: Blood (2015)
b2a2 Type bcr-abl Transcript Chronic Myelogenous Leukemia (CML) Patients in Chronic Phase (CP) on Glivec Achieve Complete Cytogenetic Remission (CCyR) Earlier Than Those with b3a2.
Authors: Elza G. Lomaia, Irina S. Martinkevich, Yulia S. Ogorodnikova, Anton A. Lyschov, Konstantin V. Bogdanov, Andrey Yu Zaritskey
Journal: Blood (2006)
Donor/Recipient Matching for the -174G/C SNP Polymorphism in the IL-6 Gene Promoter Influences the Outcome of Stem Cell Transplantation.
Authors: Cintia Manzano, Pascual Balsalobre, David Serrano, Rafael Carrion, Alfonso Gomez-Pineda, Jose Luis Diez-Martín, Ismael Buño
Journal: Blood (2005)
Phase 2 Multicenter Trial of Rabbit Anti-Thymocyte Serotherapy In Myelodysplastic Syndrome: Rate of Hematological Improvement Associated with Pre-Treatment Disease Duration
Authors: P.K. Epling-Burnette, Rami S. Komrokji, Jaroslaw P Maciejewski, Mikkael A. Sekeres, Ronald Paquette, Sheng Wei, Jeffrey S Painter, Fanqi Bai, William J Fulp, Jennifer Paleveda-Pena, Dung-Tsa Chen, Alan F. List
Journal: Blood (2010)
Activation of PP2A by FTY720 Inhibits Survival and Self-Renewal of the Ph(+) Chronic Myelogenous Leukemia (CML) CD34+/CD38− Stem Cell through the Simultaneous Suppression of BCR/ABL and BCR/ABL– independent Signals
Authors: Paolo Neviani, Ramasamy Santhanam, Yihui Ma, Guido Marcucci, John C. Byrd, Ching-Shih Chen, Jorge Cortes, Michael A. Caligiuri, Claudia Huettner, Ravi Bhatia, Denis-Claude Roy, Danilo Perrotti
Journal: Blood (2008)
Risk Factors and Mortality Associated with CMV Reactivation Post Autologous Stem Cell Transplantation.
Authors: Claudia Bley, Fabio PS Santos, Guilherme Fleury Perini, Ricardo Helman, Andreza Alice Feitosa Ribeiro, Jose Mauro Kutner, Jairo Sobrinho, Angela Tavares, Jacyr Pasternak, Fabio R. Kerbauy, Nelson Hamerschlak
Journal: Blood (2010)
CD137 co-stimulation and blocking PD-1 enhances NK cell-mediated target cell lysis by CD30/CD16A TandAb AFM13.
Authors: Xing Zhao, Narendiran Rajasekaran, Uwe Reusch, Jens-Peter Marschner, Martin Treder, Holbrook Edwin Kohrt
Journal: Journal of Clinical Oncology (2015)

3050 Background: The CD30/CD16A bispecific tetravalent TandAb antibody AFM13 recruits and activates NK cells by specific binding to CD16A for targeted lysis of CD30+ tumor cells. Given promising clinical activity and safety profile of AFM13 and proof-of-mechanism demonstrating dependence on the immune response, potential synergy of AFM13 and checkpoint inhibitors was evaluated. Methods: Efficacy was assessed by in vitro cytotoxicity with human PBMCs, enriched NKs, and CD30+ target cells as well as cell line and patient-derived xenograft in vivo models with AFM13, anti-CTLA-4, anti-PD-1, or anti-CD137 antibodies. Results: AFM13 demonstrated higher potency and efficacy toward target and effector cells relative to other CD30+ antibody formats (EC50 = 15pM). These favorable properties resulted in superior cytotoxicity when AFM13 was incubated with CD30+ tumor cells and enriched NK cells. Single treatment with AFM13 at suboptimal concentrations (1 pM) induced effector-to-target cell-dependent lysis of CD30+ lymphoma cells up to 40% using enriched NK cells. Immune-modulating antibodies alone mediated substantially lower lysis ( < 25%). However, the addition of anti-PD-1 or anti-CD137 to AFM13 strongly enhanced specific lysis up to 70%, whereas the addition of anti-CTLA-4 to AFM13 showed no beneficial effect. The most impressive increase of efficacy was observed when AFM13 was applied together with a combination of anti-PD-1 and anti-CD137. In vivo, synergy of AFM13 and CPI combination was observed with each CPI tested and augmented with anti-PD1 (regression in 9/10 tumors), ant-CTLA-4 (3/10), and anti-CD137 mAb (3/10) and influenced by presence of regulatory T cells, NK cells, and Th1 cytokines. Conclusions: Our findings support engagement of NK cells using CD30/CD16A TandAbs by binding to CD16A does not completely exploit the efficacy of NK cells. Therefore combination trials performed with companion intratumoral assessment may personalize dual-Ab therapy and augment the efficacy of AFM13 and CPIs.
Pegfilgrastim (6mg or 12mg) Mobilizes CD34+ Cells Similarly to Filgrastim (5mcg/kg/day) When Administered Following Chemotherapy in Patients with Non-Hodgkin’s Lymphoma.
Authors: Nigel Russell, Rolf Mesters, Michael Pfreundschuh, Marc Boogaerts, Hans Johnsen, Maria del Canizo, Phillippa Barker, Geoff Quinn, Norbert Schmitz
Journal: Blood (2005)
Chronic Gvhd Global Severity According to NIH Consensus Criteria: Results From the Chronic Gvhd Consortium
Authors: Sally Arai, Madan Jagasia, Mukta Arora, David Miklos, Xiaoyu Chai, Barry Storer, Paul J. Martin, Corey Cutler, Daniel J. Weisdorf, Joseph Pidala, Jeanne Palmer, Mary Flowers, David Jacobsohn, Paul A. Carpenter, Steven Z. Pavletic, Georgia B. Vogelsang, Stephanie J. Lee
Journal: Blood (2010)
Encouraging Outcomes in African-American Patients with Use of Post-Transplant Cyclophosphamide after HLA Mismatched Hematopoietic Stem Cell Transplant
Authors: David H. Aggen, Kendra Mellert, Divaya Bhutani, Lois Ayash, Lawrence G. Lum, Abhinav Deol, Voravit Ratanatharathorn, Joseph P. Uberti
Journal: Blood (2015)
Genomic and Proteomic Analysis of Primary Chemoresistance and Induction Failure in Acute Myeloid Leukemia
Authors: Fiona Brown, Eric Still, Paolo Cifani, Scott Ficarro, Gayle Pouliot, Esther Drill, Mithat Gonen, Jie He, Sohail Balasubramanian, Shan Zhong, Dean Pavlick, Bahar Yilmazel, Andrei V. Krivtsov, Todd A. Alonzo, Soheil Meshinchi, Steven M. Kornblau, Richard M. Stone, Guido Marcucci, John C. Byrd, Ross L. Levine, Scott A. Armstrong, Nathanael Gray, Jarrod Marto, Alex Kentsis
Journal: Blood (2015)
Treatment of CKD Anemia in Octogenarians: A Comparison of Epoetin Alfa (EPO) in Elderly (65–79; &gt;/=80) and Non-Elderly (&lt;65) Patients.
Authors: Jeffrey C. Fink, Behin H. Yektashenas, Michael V. Blasi, Mark A. Klausner, Richard C. Woodman, Robert Provenzano
Journal: Blood (2004)
Incidence of brain metastases after first line chemotherapy in breast cancer patients treated with or without trastuzumab
Authors: G. Ferretti, A. Felici, M. Pino, P. Carlini, A. Fabi, C. Nuzzo, I. Sperduti, F. Cognetti, P. Papaldo
Journal: Journal of Clinical Oncology (2006)

10582 Background: Brain metastases during trastuzumab therapy have been frequently observed. Only a few studies have compared the risk of brain metastases in patients (pts) treated with or without trastuzumab. Methods: In our hospital, between Jun 2000 and September 2005, we conducted a retrospective study in 72 metastatic breast cancer pts treated with first-line mono-chemotherapy (CT) with paclitaxel or docetaxel or vinorelbine ± Trastuzumab (T). Results: Thirty-five pts with HER2 pos disease were treated with T associated with 1 st line CT, while 37 pts (16 with HER2 positive tumor, 21 HER2 negative) were not treated with T (NT). Ten HER2 pos NT pts subsequently received T. The median follow-up was 21 months (range1–129); the median age was 54 (range 32–82); the median treatment duration was 5 months (range 1–29). The incidence of recurrence (R), progressive disease in brain (BR), progression free survival (PFS) after first line CT, and overall survival (OS) were reported below: (see Table) Conclusions: This study showed that, after first line chemotherapy, the use of T did not affect the incidence of BR in HER2 pos metastatic breast cancer pts. On the other hand, Her-2 neg seems to predict ‘per se‘ a lower incidence of cerebral spread of disease. [Table: see text] No significant financial relationships to disclose.